Trial Profile

A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 04 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pamrevlumab (Primary) ; Corticosteroids; Deflazacort
Indications Duchenne muscular dystrophy
Focus Registrational; Therapeutic Use
Acronyms LELANTOS-2
Sponsors Kyntra Bio

Most Recent Events

07 Jan 2026 According to FibroGen media release, FibroGen is now called as Kyntra Bio.
30 May 2024 Status changed from active, no longer recruiting to discontinued (Study did not meet its primary endpoint.)
04 Feb 2024 This trial has been discontinued in Italy,(global end of the trial 2023-10-11 )

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com